Qiu-mei Zhang

Key Laboratory Of Hormones And Development, Tianjin Key Laboratory Of Metabolic Diseases
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Protective Effects of Reduced Beta 2 Glycoprotein I on Liver Injury in Streptozotocin (STZ)-Diabetic Rats by Activation of AMP-Activated Protein Kinase.

Protective Effects of Reduced Beta 2 Glycoprotein I on Liver Injury in Streptozotocin (STZ)-Diabetic Rats by Activation of AMP-Activated Protein Kinase.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: October 25, 2018

Association of Thyroid-Stimulating Hormone Levels with Microvascular Complications in Type 2 Diabetes Patients.

Association of Thyroid-Stimulating Hormone Levels with Microvascular Complications in Type 2 Diabetes Patients.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: June 05, 2017

Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN.

Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN.

Journal: American journal of translational research

Published: February 21, 2017

Serum adipocyte fatty acid-binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus.

Serum adipocyte fatty acid-binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus.

Journal: Journal of diabetes

Published: October 04, 2016

Effects of reduced β2 glycoprotein I on high glucose‑induced cell death in HUVECs.

Effects of reduced β2 glycoprotein I on high glucose‑induced cell death in HUVECs.

Journal: Molecular medicine reports

Published: September 20, 2016

Circulating MiRNA biomarkers serve as a fingerprint for diabetic atherosclerosis.

Circulating MiRNA biomarkers serve as a fingerprint for diabetic atherosclerosis.

Journal: American journal of translational research

Published: April 16, 2016

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.

Journal: Diabetology & metabolic syndrome

Published: March 09, 2014

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.

Journal: Cardiovascular diabetology

Published: November 24, 2013

Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes.

Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes.

Journal: Diabetology & metabolic syndrome

Published: September 20, 2013

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.

Journal: Cardiovascular diabetology

Published: September 05, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026